Sunday, October 2, 2022
Home Tags Eylea

Tag: Eylea

UnitedHealthcare Insurance accuses Regeneron of kickbacks to inflate Eylea price

“Regeneron set Eylea’s price well beyond what the market would otherwise bear,” the complaint states, and left Medicare plan sponsors like United “to foot the large majority of the inflated bill.”

Regeneron’s net income jumps 40 percent to $1.3 billion in 2016

Total revenues in 2016 for Regeneron, the state’s largest biopharmaceutical employer, rose to $4.86 billion, an 18 percent increase from the previous year.

Eye drug drives eye-popping company growth

Regeneron Pharmaceuticals in Greenburgh reported more than doubling revenue in 2012, driven by $838 million in sales of its 1-year-old drug Eylea.

Regeneron named biotech’s best

Regeneron Pharmaceuticals ended November with European approval of its drug treatment for eye disease and a national award as biotechnology company of the year.

Regeneron sales boom with drug launch

Regeneron Pharmaceuticals in Greenburgh raised its 2012 sales forecast for its year-old drug Eylea by $90 million to $115 million over its earlier forecast.

Regeneron Takes Top Spot in Science Magazine Survey

Regeneron Pharmaceuticals Inc., long considered to be the cornerstone of a fast-emerging biotechnology cluster here in the Hudson Valley, was ranked the number one employer in the global biopharmaceutical industry by Science magazine.

Eylea approved for use in Japan

Regeneron Pharmaceuticals Inc. announced today that Eylea was approved for the treatment of patients with neovascular, or wet, age-related macular degeneration (AMD) in Japan.

Regeneron secures FDA approval

The U.S. Food and Drug Administration (FDA) on Sept. 21 approved Eylea Injection, developed by Regeneron Pharmaceuticals Inc., for the treatment of macular edema following central retinal vein occlusion.